Expect Biogen (BIIB) to be Down on Weaker Earnings and Guidance - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Biogen (BIIB) PT Lowered to $304 at Stifel
February 3, 2022 11:12 AM ESTStifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy rating following earnings.
The analyst commented, "Biogen's 4Q21 earnings call was fundamentally a non-event, as few specifics were offered on whether there's a feasible... More
